Multi-Analyte Platform Development

About Biolinq

Biolinq is pioneering a new category of 'Biowearables' with its needle-free, intradermal biosensor platform. The company's first FDA-cleared product, the Biolinq Shine™, is a qualitative glucose sensor for non-insulin-using adults, featuring a unique color-coded LED system for real-time feedback. With over $120 million invested and a leadership team with deep experience from companies like Dexcom and Medtronic, Biolinq aims to expand its platform beyond glucose to other biomarkers, targeting the massive metabolic health and digital wellness markets. Its core innovation lies in a comfortable, microarray sensor architecture designed for scale and multi-analyte functionality.

Therapeutic Areas